In Vitro Study of the Effect of Gadolinium Contrast on Fibrocytes

Status unconfirmed

Conditions studied: Gadolinium Toxicity

In brief

Gadolinium contrast agents are frequently administered for MRI imaging. Very little is known of its toxicity outside of patients with reduced renal function.

Key facts

Study ID

NCT02512796

Run by

University of Virginia

People needed

60

Starts

2015-07-01

Expected to finish

2017-12-01

Last updated by the study team

2015-07-31

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Renal, pancreas or liver transplant OR those without organ transplant OR controls
• Age 18-70
• Both gender
• Exposure to gadolinium contrast agents (no exposure in controls)
• Have had a transplant, have had a contrast dye with an MRI
• Have not had a transplant and have had a contrast dye with an MRI
• Healthy person who has not had an MRI or gadolinium for any other reason.

You may not qualify if…

• End stage kidney disease or Stage 5
• Previous diagnosis of Nephrogenic Systemic Fibrosis

Where it is running

• University of Virginia — Charlottesville, Virginia, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.